These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 24417707)

  • 1. Parental quality of life and depressive mood following methylphenidate treatment of children with attention-deficit hyperactivity disorder.
    Kim Y; Kim B; Chang JS; Kim BN; Cho SC; Hwang JW
    Psychiatry Clin Neurosci; 2014 Jul; 68(7):506-14. PubMed ID: 24417707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorder.
    Hwang JW; Kim B; Kim Y; Kim TH; Seo WS; Shin DW; Woo YJ; Yoo H; Lee JS; Lee JH; Lim MH; Chung YC; Jung CH; Yoo HK
    Hum Psychopharmacol; 2013 Nov; 28(6):600-7. PubMed ID: 24519694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment.
    Gürkan K; Bilgiç A; Türkoglu S; Kiliç BG; Aysev A; Uslu R
    J Psychopharmacol; 2010 Dec; 24(12):1810-8. PubMed ID: 19939861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of parent training in combination with methylphenidate treatment on family relationships for children with attention deficit/hyperactivity disorder].
    Zhang Y; Kang CY; Zhao XR; Xuan X; Ding KJ; Liu RX; Wang YJ; Yang RX; Li XR; Wan S
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):185-9. PubMed ID: 24568915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood?
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2013; 36(5):141-5. PubMed ID: 24045603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
    Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
    Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder.
    Tzang RF; Wang YC; Yeh CB; Hsu CD; Liang HY; Yang PC; Liu HJ; Huang YS; Cheng H; Hsu YC; Liu SI; Pan CH; Huang YF; Huang CF; Wu YY; Huang YH; Liu HC; Chang HL
    Psychiatry Clin Neurosci; 2012 Feb; 66(1):53-63. PubMed ID: 22250610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder.
    Salatino-Oliveira A; Genro JP; Zeni C; Polanczyk GV; Chazan R; Guimarães AP; Callegari-Jacques SM; Rohde LA; Hutz MH
    Biol Psychiatry; 2011 Aug; 70(3):216-21. PubMed ID: 21550019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
    Yang P; Hsu HY; Chiou SS; Chao MC
    Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate.
    Wang LJ; Chen CK; Huang YS
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):246-53. PubMed ID: 25574708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender Differences in the Behavioral Symptoms and Neuropsychological Performance of Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate: A Two-Year Follow-up Study.
    Wang LJ; Chen CK; Huang YS
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):501-8. PubMed ID: 26262904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.
    Rösler M; Ginsberg Y; Arngrim T; Adamou M; Niemelä A; Dejonkheere J; van Oene J; Schäuble B
    World J Biol Psychiatry; 2013 May; 14(4):282-90. PubMed ID: 21517701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission Rate and Functional Outcomes During a 6-Month Treatment With Osmotic-Release Oral-System Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder.
    Su Y; Li H; Chen Y; Fang F; Xu T; Lu H; Xie L; Zhuo J; Qu J; Yang L; Wang Y
    J Clin Psychopharmacol; 2015 Oct; 35(5):525-34. PubMed ID: 26267421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
    Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.